US · Healthcare · Biotechnology
EPS came in at -0.43 against a street estimate of -0.53 — a beat of 18.9%.
Analysts rate Elicio Therapeutics Inc. a strong buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $13.67.
| Fund | Stake |
|---|---|
| Knoll Capital Management LP | 4.61% |
| BlackRock Inc | 2.91% |
| Vanguard Capital Management, LLC | 2.18% |
| Geode Capital Management, LLC | 1.18% |
| State Street Corp | 0.68% |
| Northern Trust Corp | 0.50% |
| Ikarian Capital, LLC | 0.38% |
| Vanguard Portfolio Management, LLC | 0.34% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Elicio Therapeutics Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.